Skip to Main Content
Menu Button
About Alkeus
Our science
Disease areas
Patients
News
Careers
News
View All
View All
Press Release
Publications
Search
Search for:
Alkeus Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 10, 2024
December 21, 2023
Learn more
Alkeus Pharmaceuticals Presents Positive Gildeuretinol Trial Results at American Academy of Ophthalmology, Demonstrating Significant Slowing of Retinal Atrophic Lesions in Stargardt Disease
November 3, 2023
Learn more
Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for gildeuretinol (ALK-001) in the Treatment of Stargardt Disease
June 5, 2023
Learn more
ALK-001 (C20-D3-Vitamin A) slows the growth of atrophic lesions in ABCA4-related Stargardt Disease: Results of a Phase 2 placebo-controlled clinical trial (TEASE study)
June 1, 2022
Learn more
C20D3-Vitamin A Prevents Retinal Pigment Epithelium Atrophic Changes in a Mouse Model
December 1, 2021
Learn more
Alkeus Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 29, 2021
Learn more
Vitamin A cycle byproducts impede dark adaptation
September 1, 2021
Learn more
FDA Grants Alkeus Pharmaceuticals Breakthrough Therapy Designation for ALK-001 (C20-D3-vitamin A) for the Treatment of Stargardt Disease
July 14, 2021
Learn more
1
2
3
4
5